KORU Medical Systems, Inc. (KRMD)
| Market Cap | 189.77M +80.4% |
| Revenue (ttm) | 41.13M +22.2% |
| Net Income | -2.64M |
| EPS | -0.06 |
| Shares Out | 46.51M |
| PE Ratio | n/a |
| Forward PE | 132.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,688 |
| Open | 3.940 |
| Previous Close | 3.960 |
| Day's Range | 3.940 - 4.056 |
| 52-Week Range | 2.350 - 6.608 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+59.31%) |
| Earnings Date | May 6, 2026 |
About KRMD
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver,... [Read more]
Financial Performance
In 2025, KORU Medical Systems's revenue was $41.13 million, an increase of 22.23% compared to the previous year's $33.65 million. Losses were -$2.64 million, -56.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for KRMD stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 59.31% from the latest price.
News
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializat...
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Earnings Call Transcript: Q4 2025
Revenue grew 22% year-over-year to $41.1M in 2025, with strong domestic and international gains, positive adjusted EBITDA, and cash flow. 2026 guidance projects 15%–22% revenue growth, continued profitability, and new product launches, amid a CEO transition.
KORU Medical Systems Announces CEO Transition
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercializat...
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercializa...
KORU Medical Systems Transcript: Piper Sandler 37th Annual Healthcare Conference
Year-to-date growth exceeded 20%, fueled by international expansion, U.S. market outperformance, and prefill technology. New drugs and products are set to drive further gains, with margin improvement and cash flow positivity supporting a robust outlook.
KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume ...
KORU Medical Systems to Participate in Upcoming Investor Conferences
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercializat...
KORU Medical Systems Earnings Call Transcript: Q3 2025
Q3 revenue grew 27% year-over-year, led by strong SCIG and international expansion, with gross margin at 60.2%. Full-year guidance was raised to $40.5M-$41M, and 2026 growth is expected to remain above 20%. Oncology and prefilled conversions are key future drivers.
KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report Third Quarter 2025 Financial Results on November 12, 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy
DENVER & MAHWAH, N.J.--(BUSINESS WIRE)--ForCast Orthopedics, Inc. and KORU Medical Systems, Inc. (NASDAQ: KRMD) today jointly announced an agreement leveraging KORU Medical's FreedomEDGE® infusion sys...
Cirtec Medical Announces Appointment of New Chief Executive Officer
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is ...
KORU Medical Systems Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Strong recurring revenue, international expansion, and new product launches are driving 20%+ growth, with four new drugs expected to be approved in the next year and a robust pipeline targeting oncology and rare diseases. International growth and product innovation remain key priorities.
KORU Medical Systems Earnings Call Transcript: Q2 2025
Q2 revenue grew 21% to $10.2M, driven by strong domestic and international performance, with raised 2025 guidance to $39.5–$40.5M. Gross margin remains robust despite tariff pressures, and positive cash flow is expected for the year. International expansion and new product launches are key growth drivers.
KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...